FDA approves Gilead Sciences’ Epclusa for chronic HCV: 4 observations

The FDA has approved Gilead Sciences’ Epclusa to treat adults with chronic hepatitis C, both with and without cirrhosis.

Advertisement

Here are four observations:

1.  Epclusa is a fixed-dose combination tablet.

2. The drug is approved for use in combination with ribavirin for patients with moderate to severe cirrhosis.

3. Epclusa’s most common side effects are headache and fatigue.

4. Gilead Sciences has courted controversy in the past. The company’s Sovaldi and Harvoni drugs, also intended for HCV treatment, were criticized for their high prices.

More articles on GI/endoscopy:
4 key trends in the $2.35B GI/endoscopic devices market
Merit Health Natchez adds Dr. W. Kirk Mullins: 4 points
5 most read GI/endoscopy stories: June 20 — June 24

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.